Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Beth Israel Deaconess Medical Center
With
Amgen
Age
0–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
AML, ALL,CML Chronic Phase, Accelerated Phase, or Blast Crisis, CLL, MDS, RELAPSED NON-HODGKIN'S OR HODGKIN'S LYMPHOMA, Aplastic Anemia, Multiple Myeloma, MYELOPROLIFERATIVE DISORDER (P Vera, CMML, ET
Age less than 65 years
Patients must have a healthy family member who is HLA-identical to the recipient or has 1 antigen mismatch and who is willing to receive a course of G-CSF and undergo 2-4 daily leukaphereses
Each patient must sign an informed consent and be willing to participate as a research subject after having been advised of the nature and risk of the study prior to entering protocol
Absence of hematologic or marrow function related diseases that interferes with the collection of sufficient numbers of normal progenitor cells
Absence of any medical condition that would pose a serious health risk by undergoing peripheral blood stem cell harvest
Negative HIV, HTLV-1, Hepatitis B surface antigen and Hepatitis C
The donor must be blood relation. A prospective related donor must be at least genotypically HLA-A, B, DR identical to the patient, but can differ for 1 HLA-locus.
You may not be if
Active CNS involvement
Females who are pregnant or breast feeding
ECOG performance status \> 1. Karnofsky performance status \< 80%
LVEF \< 40%
Active viral, bacterial, or fungal infection
Patients seropositive for HIV; HTLV -1
Patients not providing informed consent
Patients with known hypersensitivity to E. Coli derived product
A positive HIv infection or HTLV - 1 test or evidence of active/persistent viral hepatitis infection. Presence of any medical condition that would pose a serious health risk by undergoing peripheral blood stem cell harvest. Donors with known hypersensitivity to E. Coli derived products.
Clareo Health | Nonmyeloablative Allo SCT for the Treatment of Hematologic Disorders
